Kyntra Bio (NASDAQ:KYNB) Stock Rating Upgraded by HC Wainwright

Kyntra Bio (NASDAQ:KYNB) was upgraded by equities researchers at HC Wainwright to a “strong-buy” rating in a research report issued on Friday,Zacks.com reports.

A number of other equities analysts have also recently weighed in on KYNB. Weiss Ratings began coverage on Kyntra Bio in a research note on Wednesday, January 14th. They issued a “sell (d+)” rating on the stock. Zacks Research downgraded shares of Kyntra Bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold”.

Kyntra Bio Stock Performance

Shares of NASDAQ KYNB opened at $6.93 on Friday. The firm has a market capitalization of $28.07 million, a P/E ratio of 0.13 and a beta of 0.83. Kyntra Bio has a 52-week low of $4.85 and a 52-week high of $12.60.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.